Mostrar el registro sencillo del ítem
dc.contributor.author | Giovannoni, Gavin | |
dc.contributor.author | Boyko, Alexey | |
dc.contributor.author | Correale, Jorge | |
dc.contributor.author | Edan, Gilles | |
dc.contributor.author | Freedman, Mark S. | |
dc.contributor.author | Montalban, Xavier | |
dc.contributor.author | Rammohan, Kottil | |
dc.contributor.author | Stefoski, Dusan | |
dc.contributor.author | Yamout, Bassem | |
dc.contributor.author | Leist, Thomas | |
dc.contributor.author | Aydemir, Aida | |
dc.contributor.author | Borsi, Laszlo | |
dc.contributor.author | Verdun di Cantogno, Elisabetta | |
dc.date.accessioned | 2023-12-12T13:55:36Z | |
dc.date.available | 2023-12-12T13:55:36Z | |
dc.date.issued | 2023-04-03 | |
dc.identifier.citation | Giovannoni G, Boyko A, Correale J, Edan G, Freedman MS, Montalban X, Rammohan K, Stefoski D, Yamout B, Leist T, Aydemir A, Borsi L, Verdun di Cantogno E. Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study. Mult Scler. 2023 May;29(6):719-730. doi: 10.1177/13524585231161494 | es_ES |
dc.identifier.uri | https://doi.org/10.1177/13524585231161494 | |
dc.identifier.uri | https://repositorio.fleni.org.ar/xmlui/handle/123456789/906 | |
dc.description.abstract | Background: CLASSIC-MS evaluated the long-term efficacy of cladribine tablets in patients with relapsing multiple sclerosis. Objective: Report long-term mobility and disability beyond treatment courses received in CLARITY/CLARITY Extension. Methods: This analysis represents CLASSIC-MS patients who participated in CLARITY with/without participation in CLARITY Extension, and received ⩾1 course of cladribine tablets or placebo (N = 435). Primary objective includes evaluation of long-term mobility (no wheelchair use in the 3 months prior to first visit in CLASSIC-MS and not bedridden at any time since last parent study dose (LPSD), i.e. Expanded Disability Status Scale (EDSS) score <7). Secondary objective includes long-term disability status (no use of an ambulatory device (EDSS < 6) at any time since LPSD). Results: At CLASSIC-MS baseline, mean ± standard deviation EDSS score was 3.9 ± 2.1 and the median time since LPSD was 10.9 (range = 9.3-14.9) years. Cladribine tablets-exposed population: 90.6% (N = 394), including 160 patients who received a cumulative dose of 3.5 mg/kg over 2 years. Patients not using a wheelchair and not bedridden: exposed, 90.0%; unexposed, 77.8%. Patients with no use of an ambulatory device: exposed, 81.2%; unexposed, 75.6%. Conclusion: With a median 10.9 years' follow-up after CLARITY/CLARITY Extension, findings suggest the sustained long-term mobility and disability benefits of cladribine tablets. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Sage | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Cladribine | es_ES |
dc.subject | Cladribina | es_ES |
dc.subject | Immunosuppressive Agents | es_ES |
dc.subject | Inmunosupresores | es_ES |
dc.subject | Multiple Sclerosis | es_ES |
dc.subject | Esclerosis Múltiple | es_ES |
dc.subject | Neoplasm Recurrence | es_ES |
dc.subject | Recurrencia de Neoplasia | es_ES |
dc.title | Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.description.fil | Fil: Correale, Jorge. Fleni. Departamento de Neurología. Servicio de Neuroinmunología y Enfermedades Desmielinizantes; Argentina. | |
dc.relation.ispartofVOLUME | 29 | |
dc.relation.ispartofNUMBER | 6 | |
dc.relation.ispartofPAGINATION | 719-730 | |
dc.relation.ispartofCOUNTRY | Reino Unido | |
dc.relation.ispartofCITY | Londres | |
dc.relation.ispartofTITLE | Multiple sclerosis | |
dc.relation.ispartofISSN | 1477-0970 | |
dc.type.snrd | info:ar-repo/semantics/artículo | es_ES |